Rodolfo Rohr, LarmorBio - High-Resolution Molecular Phenotyping | LSI USA '24

Rodolfo Rohr  0:04  
Good morning, everyone. Thank you for being here. Quick Intro, Rodolfo Rohr, founding CEO of Larmor. Bio. As for my background, I was trained in electrical engineering. Formerly, I was president and CEO of interactive motion technologies, and MIT spinoff that pioneered the use of medical robots in neuro recovery. Today, our emotion robots continue to make a positive impact in stroke patients lives all over the world. So now to to my new company, so our more bio is actually, you know, probably it's a really exciting company. So essentially, we've repurposed a magnetic resonance scanner into a compact IVD to scan minimally invasive, small blood samples. Oh, I need to so actually, this is the first time ever we're actually introducing the device into the to the public, to the investment community. We actually have significant traction, significant traction in in multiple, multiple customers, pharma companies and clinical research. Let me just put this thing there. So why are we focusing card metabolic risk? Well, essentially near 50% of all heart attacks and strokes occur in people with normal lab results. So this is a problem that our customers are trying to solve, and this became our problem at Larmor bio as we try to help them uncover hidden cardiometabolic risks. So for instance, this is a Quest Diagnostics. They currently offer an oxidative stress test to try to uncover hidden cardiometabolic risks. They use a biomarker called f2 ISOP. And this is, again, it's an emerging biomarker to help assess risk in cardiometabolic diseases. So cardiometabolic diseases, right? We're talking about diabetes, obesity, kidney disease and cardiovascular disease. So oxidative stress testing has the potential to significantly make an impact in early detection of complications associated with these diseases. Now the problem is that the current standard of care is, is, actually, is quite inadequate. It's a proxy for oxidative stress. It measures one specific byproduct of oxidative stress from urine is actually a ratio of isoprosity molecules with urinary creatinine, so the results sometimes have are prone to confounding factors, and it's somewhat difficult for it to become a clinically relevant marker because it's hard to for this marker to catch the effects of disease modifying therapeutics on on patient populations. Furthermore, it's a slow process. It's, again, we're talking about centralized lab. The samples need to be sent out to centralized lab. It's a massive instrument, high cost. And really the I would say the the most, the highest cost, is that, you know, it's actually not used in routine Cardiometabolic Health screening today. It's just used as an ad hoc, you know, method. So this is the problem we're trying to solve. So we've again, this is our instrument. We use magnetic resins to detect the the the oxidative stress directly from blood, and with that, we're able to quantify cardiometabolic disease progression. We are able to provide a faster, more accurate and more efficient solution that can be deployed at the point of care, and this has been extensively tested in clinical settings, as I don't know if I mentioned in the beginning, but we're an MIT spinoff, but we have a strong existing collaboration with multiple research hospitals all over the world. This is actually data from the National University Hospital in Singapore, and here you can clearly see. How are more bio can add to the diagnostic accuracy of the current standard of care? Again, not going to get into the details of this of the graph, but essentially, 50% superior diagnostic accuracy. And this market is actually a growing lucrative, high margin business supported by instrument sales, recurring revenue, through consumables and analysis, through software, through software services. According to market forecast is this market is supposed to nearly triple over the next decade, and we are ready, feeling this, this in, you know, in our company, we are a two year old spin off, and we are already booking revenue with, with some of the leading pharma companies in the world. We're not, these are, aren't all of our customers, but I'm just saying these are, we actually have one of these customers already. And we're, we're actually continue to to, you know, we're, this is, this is our space. We're actually, you know, helping the GLP one drug space uncover, essentially develop better therapeutics that can actually reduce oxidative stress and measure it, quantify it. So a natural progression for for our company is as we achieve our regulatory milestones, which, for this first step is actually quite simple. It's a, it's a, basically a lab based certification. So we have a strong trajectory to go into clinical trial testing, and we're certainly not going to compete with quest and LabCorp, but we imagine we actually started discussions with a lot of the large players to see how we can partner to potentially offer our test through their through their their network. So again, this is, you know, oxidative stress testing is, is an existing market, a growing market, and we have a substantial competitive advantage with our team, our technology and our strong momentum in the marketplace. But we're not going to stop here again. I will go back to this, to this. This is, this is our instrument. This is the, actually, this is our this is our alpha. You know, we still don't have a real specific name for it, but this is already deployed in three continents through our early stage spin on. So our vision is really to enable oxidative stress testing to help inform clinical decision making. Now this is a big, huge challenge, which wouldn't be possible if we aren't partnering with if we have extensive global partner network to help run the extensive clinical validation that's needed for oxidative stress to become part of routine, routine clinical care and management. These are some of our logos. Unfortunately, the big farmer. We this is one big farmer. We're anticipating another one coming on board. This year, we've submitted abstracts to the American Diabetes Association and The Endocrine Society meeting, where we'll be publishing some of the results from our recent collaborations. We're expecting clinical data read out in over 1500 patients that are currently being tested in this methodology all over the world in various indications, all cardiometabolic related indications, and we are naturally getting our laboratory instrument certification, which, again, that should help us scale significantly our revenue streams in the near term. But you may be thinking, Well, why am I here, right? It seems like this company is, you know, so actually, again, we want to launch this in clinical settings, so we are actually have a pretty well we have a pretty well mapped out product roadmap, which includes specific indications, you know, the use of Our methodology and specific clinical indications. So we're expecting a 2026, clearance, and really this is going to enable a completely new product category in oxidative stress testing.

Speaker 1  9:53  
So this is why we're here. We're actually launching this is the first time that the investment community gets. Opportunity to invest in our company. And, you know, I don't know if the series A or seed, or whatever you want to call it, but, you know, we're looking for $18 million and really, we're going to start really scaling our commercial operations. We're going to, you know, really file a substantial, you know, substantial IP portfolio, which you already have licensed from MIT in Singapore, but we're, we've actually filed several patents. We're continuing to file whole sort of category level patents, continue to advance our product, and again, our clinical diagnostic pipeline. That's that's really our core, and this is one of my co founders, and well, actually, there are so many other, I mean, but I wish you could put everybody's picture, but I think yes. So anyway, this is, this is our team, and, you know, experienced, you know, both in med tech, biotech and with extensive commercial background to, you know, really enable this technology to be the new standard of care in oxidative stress testing, you know, as again, this is our current customer base, our, you know, pharma companies and clinical research settings. But I think you could all sort of imagine where this could could end up being in the near term, right? So if I haven't talked to you this week, it would be a pleasure to to to see how you could potentially join our team as as as one of our investors. You.